Exploring Cryopreservation: The Future of Medical Biostasis

SUMMARY

Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe. His journey reflects a commitment to advancing medical biostasis and making preservation technologies more accessible to the public.

Tomorrow.bio addresses a significant gap in European cryopreservation services, offering both whole-body and brain-only preservation with a transparent pricing model. The company has successfully secured €5 million in funding, showcasing strong investor confidence in the potential of cryopreservation.

Kendziorra's passion for longevity drives his mission to help people extend their lives. He views Tomorrow.bio as his life's work, emphasizing the importance of bridging the gap between basic and translational science.

The company has cryopreserved over 30 human patients and 10 pets, providing critical insights into the operational and emotional challenges of the process. Kendziorra acknowledges the need for clear communication regarding the limitations of current technology.

Tomorrow.bio's business model is based on a growing membership, with over 1,000 individuals enrolled for cryopreservation, each costing approximately €200,000. The company aims to reduce costs and increase accessibility as demand grows.

Kendziorra emphasizes the ethical implications of cryopreservation, noting that while it offers a better chance of revival than traditional burial, it is not a guarantee. The future of this technology hinges on advancements in medical science.

XDETAIL

INFO

YOUTUBE2026-05-28eu-startups

OPEN SOURCE

The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio

STANCE

00:00

05:00

10:00

15:00

20:00

25:00

30:00

35:00

40:00

9 intervals • swipe left

The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio

eu-startups • 2026-05-28 09:07:18 UTC

Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe.

STANCE

STANCE MAP

Proponents of Cryopreservation

Advocate for cryopreservation as a viable alternative to traditional burial, offering potential for future revival
Highlight the growing interest and investment in cryopreservation technology, indicating a shift towards acceptance

Skeptics of Cryopreservation

Question the ethical implications and long-term viability of cryopreservation without guaranteed revival

Neutral / Shared

Acknowledge the current limitations of cryopreservation technology and the need for clear communication with clients
Recognize the potential for future advancements in medical science to impact the field of cryopreservation

FULL

00:00–05:00

Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe.

Dr. Emil Kendziorra shifted from a career in cancer research to establish Tomorrow.bio, a leading cryopreservation company in Europe that focuses on preserving both humans and pets
Tomorrow.bio addresses the gap in European cryopreservation services, offering a unique position in the market with a transparent pricing model
Kendziorras transition to cryomedicine reflects his commitment to making advanced preservation technologies more accessible to the public
The company has successfully secured €5 million in funding, showcasing strong investor confidence in the potential of cryopreservation and medical biostasis
The discussion reveals the operational and emotional challenges encountered during the preservation of the first 20 human patients and 10 pets, highlighting the need for clear communication regarding the limitations of current technology

FULL

05:00–10:00

Dr. Emil Kendziorra founded Tomorrow.bio to advance cryopreservation and medical biostasis, driven by a lifelong passion for longevity.

Dr. Emil Kendziorras passion for longevity and innovation drives his mission to help people extend their lives
His motivation to enter medicine and research is rooted in a personal belief in the value of life, rather than a specific traumatic event
Kendziorra initially aimed to obtain both an MD and a PhD to bridge the gap between basic and translational science, ultimately leading to the creation of a longevity-focused company
He considers Tomorrow.bio his lifes work, viewing previous ventures as essential steps toward tackling the complex issue of human mortality
The establishment of Tomorrow.bio marks a significant transition from traditional medical research to the pioneering field of cryopreservation, which he believes has great potential for future advancements in longevity

FULL

10:00–15:00

Dr. Emil Kendziorra founded Tomorrow.bio to advance cryopreservation and medical biostasis, viewing it as a significant solution for extending human life.

Dr. Emil Kendziorra views cryopreservation as a complex yet impactful solution for extending human life, stemming from his extensive background in biological research
His entrepreneurial journey through various startups culminated in the founding of Tomorrow.bio, which he regards as his lifes work due to its potential to advance longevity
Kendziorra emphasizes the financial viability of cryopreservation, positioning it as both a mission-driven initiative and a promising business opportunity
He acknowledges the current limitations of cryopreservation technology, particularly the challenges surrounding the gap between preservation and potential revival, and stresses the need for transparent communication with patients
Tomorrow.bio has successfully cryopreserved over 20 human patients and 10 pets, providing critical operational and emotional insights that shape their practices

FULL

15:00–20:00

Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.

Cryopreservation offers a viable alternative for individuals with terminal illnesses, allowing them to choose preservation over traditional burial or cremation, with the hope of future medical advancements
Tomorrow.bios business model is based on a growing membership, with over 1,000 individuals enrolled for cryopreservation, each costing approximately €200,000, indicating substantial revenue potential
The company is structured to provide long-term care for preserved individuals through a nonprofit foundation, which serves as a legal guardian, thereby mitigating financial risks associated with preservation
Success is measured in three stages: financial viability through membership growth, successful preservation in animals as a precursor to human trials, and the eventual revival of preserved individuals, which may take decades
Investors in Tomorrow.bio typically have a long-term investment perspective, including family offices and ultra-high-net-worth individuals, reflecting the unique nature of the cryopreservation market

METRICS

REVENUE

200,000 eurosEUR

details

CONTEXT: cost per cryopreservation

WHY: This indicates substantial revenue potential for the company

EVIDENCE: each cryo preservation is 200,000 euros

FULL

20:00–25:00

Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.

Cryopreservation does not currently ensure revival, as it depends on future technological advancements, making it a riskier alternative to traditional burial or cremation
Dr. Kendziorra notes that while cryopreservation may offer a better chance of revival than cremation, the exact probabilities remain uncertain and hinge on future medical developments
The high cost of cryopreservation is attributed to limited demand and the need for specialized medical teams, but economies of scale could significantly lower prices as adoption increases
Tomorrow.bio plans to enhance accessibility by reducing cryopreservation costs to approximately €25,000 as the technology becomes more mainstream
The introduction of brain-only preservation provides a more affordable option, although whole-body preservation is still recommended for optimal outcomes

FULL

25:00–30:00

Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.

The cost of cryopreservation is expected to decrease significantly as participation increases, benefiting from economies of scale in storage and operations
Many clients currently finance cryopreservation through life insurance policies, alleviating the burden of upfront costs
Brain-only cryopreservation is offered as a more affordable alternative to whole-body preservation, while still aiming to maintain the individuals identity and consciousness
Future technological advancements, such as 3D printing of body parts, could potentially enable revival after long-term cryopreservation, although this is not expected in the near term
The creation of a European cryopreservation organization was motivated by the need for improved medical response capabilities, which were insufficient in existing American services

FULL

30:00–35:00

Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.

Dr. Emil Kendziorra highlights Tomorrow.bios rapid growth, claiming it is 20 times faster than legacy organizations, and emphasizes improvements in cryopreservation quality and accessibility
He stresses the importance of market education over competition, noting that Tomorrow.bio currently faces no direct competitors in Europe, allowing the company to focus on informing potential clients about cryopreservation benefits
Kendziorra addresses the shift in perception of cryopreservation from a fringe concept to a legitimate option for terminally ill patients, often considered only after other medical treatments have failed
He discusses the financial aspects of cryopreservation, indicating that life insurance policies can help manage costs, making the service more accessible for interested individuals
The conversation includes the potential impact of future technologies, such as 3D printing of organs, which could improve the chances of reviving individuals who have undergone cryopreservation

FULL

35:00–40:00

Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.

Dr. Emil Kendziorra stresses the importance of increasing the number of companies in the cryopreservation sector to improve market education and establish credibility for the technology
He notes the initial focus on human cryopreservation at Tomorrow.bio, which later expanded to include pets, reflecting a rising interest in preserving animals
Kendziorra shares his personal commitment to cryopreservation, indicating that he would choose this option over traditional burial or cremation if faced with a terminal illness
The lack of competition in Europe positions Tomorrow.bio as a leader in cryopreservation, emphasizing quality and accessibility in their services
He discusses potential innovations in related fields, such as organ bio-banking and cell preservation, highlighting a mission-driven approach to broaden the applications of cryopreservation technology

FULL

40:00–45:00

Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.

Dr. Emil Kendziorra highlights the importance of effective communication to enhance public awareness and acceptance of cryopreservation, noting that approximately 20% of individuals in Europe and the US show interest in this option
He believes that reaching a milestone of 100,000 sign-ups would necessitate demonstrating the effectiveness of cryopreservation through research, potentially creating a cycle of increased interest and investment
Kendziorra suggests that endorsements from celebrities and influential figures could help legitimize cryopreservation, making it more attractive to the public and fostering broader acceptance
He argues that the decision between cryopreservation and traditional burial or cremation should be straightforward, as cryopreservation offers the potential for future revival, presenting a compelling alternative for those with terminal conditions

CRITICAL ANALYSIS

The assumption that cryopreservation will become a widely accepted practice overlooks the ethical implications and the long-term viability of revival. Inference: The lack of clear communication about the limitations of current technology may lead to unrealistic expectations among potential clients, complicating the decision-making process. Without addressing these confounders, the market may face significant backlash if revival does not meet anticipated timelines.

METRICS

revenue

200,000 euros EUR

cost per cryopreservation

This indicates substantial revenue potential for the company

each cryo preservation is 200,000 euros

THEMES

#biotech#cryopreservation#medical_biostasis#future_revival#longevity#medical_innovation#startup_ecosystem#biostasis#future_technology#medical_biastasis

DISCLAIMER

This analysis is an original interpretation prepared by Art Argentum based on the transcript of the source video. The original video content remains the property of the respective YouTube channel. Art Argentum is not responsible for the accuracy or intent of the original material.